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AbstractMetformin, an oral anti-diabetic agent in the biguanide class is a widely prescribed drug to treat high bloodglucose in patients with type 2 diabetes mellitus. Metformin has three different roles, including blood glucoseregulatory effect, protection of kidney tubular cell by acting as an effective antioxidant and finallyameliorative effect on diabetic kidney disease through saving the podocytes. Therefore, diabetic patients maybenefit from all of these three distinct ameliorative effects.
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IntroductionDiabetes mellitus is now the major cause of end-stage renal failure around the world in bothdeveloped and underdeveloped countries[1,2]. It isthe primary diagnosis causing renal failure in 20–40% of people starting treatment for end-stagekidney failure worldwide[2-4]. Vascular andglomerular damages have been found the mainfeatures of diabetic nephropathy, however tubularatrophy also plays a major role in the disease[3,4].
Mechanisms of Diabetic Kidney DiseaseApoptosis contributes to the development ofdiabetic kidney disease[5,6]. It is possible that highglucose enhances apoptosis, a form ofprogrammed cell death displayed by cellshrinkage, DNA fragmentation or chromatin
condensation in a variety of cell types, especiallyrenal proximal tubular epithelial cells[7,8].Moreover, diabetic kidneys are mainly prone toacute tubular injury in various clinical situations,such as dehydration or post renal obstruction[8-10].It is also well determined that hyperglycemia byitself is an independent risk factor for acutetubular injury under these conditions. High bloodglucose activates the generation of free radicalsand oxidative stress in tubular cells. Reactiveoxygen species (ROS) are thought to be importantmediators for several biologic responses includingproliferation and apoptosis[8-13]. Indeed, besidesapoptosis of proximal tubular epithelial byhyperglycemia, other cell types includingpodocytes will also be affected byhyperglycemia[10-13]. Thus one of beneficialtreatments in the diabetic kidney disease is usingmedication for inhibiting or reducing apoptosis tosave renal tubular cells and podocytes. In a studyon patients with type 2 diabetes mellitus (T2DM),inhibition of the rennin-angiotensin–aldosterone
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system using an angiotensin converting enzyme(ACE) inhibitor or blocking the effect ofangiotensin II through using an angiotensinreceptor blocker decreased the progression fromnormoalbuminuria to microalbuminuria[12-19] andslowed the development of end-stage renaldisease (ESRD)[15-20]. Thus, the use of an ACEinhibitor or angiotensin receptor blocker (ARB) orcombination of both is now standard therapy forpatients with diabetic nephropathy along withglucose, lipid and blood pressure control[2-9].
Renoprotective Effects of MetforminMetformin, an oral anti-diabetic agent in thebiguanide class is a widely prescribed drug totreat high blood glucose in patients withT2DM[21,22]. Recent studies have recognized thatmetformin possesses antioxidant effects, too.Reduction of apoptosis, in endothelial cells as wellas inhibition of vascular endothelial celldysfunction was also found during metformintreatment[23-25]. The beneficial action of this drugis achieved through activation of adenosinemonophosphate-activated protein kinase (AMPK).This enzyme plays an important role in protectingcellular functions under energy-restrictedconditions. Many evidences, confirm that AMPKactivation by metformin is secondary to its effecton the mitochondria as the primary target of thisdrug. There is evidence that the beneficial effect ofmetformin might be due to its mild inhibition ofthe mitochondrial respiratory chain, while theserious role of mitochondria in cell death is ofsignificance, and protecting the mitochondria hasbecome a pro-survival cell strategy [16-25]. It ispossible that the role of mitochondria inprogrammed cell death is associated with therelease of apoptotic signaling molecules. ROSproduction by mitochondria may also leadsignificantly to cell injury. Some years ago,Morales et al found that gentamicin-induced renaltubular injury is abolished by metformin[26]. It isclear that, reactive oxygen species play a key rolein the toxicity of gentamicin, resulting in acutekidney injury, and gentamicin is a mitochondrialtoxin that can imply its toxic effects when excretedby the kidney. Mitochondrial toxicity can also be
mediated by ROS as mentioned above[13,19,20,22-25].ROS is normally produced at low levels bymitochondria, conversely under pathologicalsituations the intracellular and intramitochondrial ROS content may be increased.When in certain conditions, intracellular ROScontent reaches a toxic level, results in oxidativedamage to the mitochondria causing cell death andmalfunctioning of the organ[13,19, 20,22-25]. To test thepotential renoprotective effects of metforminagainst gentamicin-induced renal damage and alsofinding out whether postponed treatment withmetformin in acute kidney injury exerts similarbenefits on gentamicin renal toxicity, weconducted a study on rats. In this study,metformin protected and also improvedgentamicin- induced acute renal injury, hence, thisdrug might be effective for protection of tubularcells[27]. More recently, we also investigated theefficiency of co-administration of garlic juice andmetformin for protection against gentamicin-kidney tubular injury in 70 rats. The results of thisinvestigation showed that metformin and garlicextract or their combination have both curativeand protective property against gentamicin renal-toxicity[28]. Accordingly, Li and colleagues showedthat co-administration of metformin andgentamicin for 13 days efficiently reversedgentamicin-induced kidney injury[29]. Thus, thesefindings provide further evidence for theattribution of metformin in its kidney protectiveefficacy besides its well-known blood glucoseregulatory action[22-28].While, diabetic kidney disease is one of themost important complications of this illness[29-36]and metformin is widely used in this patients,especially in T2DM, recently much attention hasalso been directed on the possible protective andameliorative properties of metformin in diabeticrenal disease. Hyperglycemia intensifies oxidativestress and generation of ROS, which have a criticalrole in the pathogenesis of diabetic renaldisease[23-30]. Indeed, metformin treatment causedsignificant restoration in diabetic renal disease-induced oxidative stress mRNA levels[23-27].Various evidences suggest that ROSoverproduction may be the key starting event thatresults in long-term development of problems ofdiabetes. ROS generation by oxidative stresscauses cell death[20-27]. As it was mentionedpreviously, apoptosis is implicated in the
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pathogenesis of diabetic nephropathy and ROS isan inducer of apoptosis in various cell typescontaining podocytes[22-27]. Interestingly Kim et alconducted a study using metformin in diabeticrats. They observed the repair of podocytes bymetformin treatment in diabetic rats. Theysuggested that diabetes-induced podocyte loss indiabetic nephropathy could be diminished bymetformin[37-40]. They also found that the densityof podocytes decreases in diabetic rats along withincreased albumin excretion. Podocyte apoptosishas been identified to associate with increasingalbuminuria. Moreover, there are evidences forthe role of intracellular ROS as potent inducers ofpodocyte apoptosis. Kim et al also observed thatthe phosphorylation of AMPK was decreased inthe kidney of diabetic rats, and metformin couldreestablish its alteration. Therefore, metforminmight exert some of its effects by amendment ofrenal oxidative stress[34]. Thus one might suggestmetformin to inhibit the advanced glycation end-products and improve the free-radical defensesystem, hence, preventing the diabetic renalinjury[3].It is well understood that the injury to thepodocytes leads to occurrence of proteinuria[32-36].Therefore the loss of glomerular podocytesprecedes and predicts the onset of diabeticnephropathy and may be an early pathologicalmanifestation of diabetic kidney disease.Metformin significantly decreased albuminuria inpatients with T2D[34,39,40]. Previous studies havealso shown the beneficial effects of metformin onreduction of macrovascular morbidity andmortality, suggesting anti-atherogenic, antioxidantand anti-inflammatory effects[21-25]. Furthermore,metformin significantly decreased albuminuria inpatients with T2DM[40-43].
ConclusionTherefore, it is reasonable to interpret thatmetformin has three different roles, including:blood glucose regulatory effect, protection ofkidney tubular cell by acting as an effectiveantioxidant and finally ameliorative effect ondiabetic kidney disease through saving thepodocytes. Therefore, diabetic patients may
benefit from all of these three distinctameliorative effects. However, it should be notedthat, according to the contraindication ofmetformin in the estimated glomerular filtrationrates (eGFR) of less than 30 mL/minute, wecannot suggest this drug for renal tubular cellprotection in human studies. Hence, we suggest tomore investigation on this subject.
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